Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CUMBERLAND PHARMACEUTICALS INCCPIX · Entity 6757 | Director | March 18, 2026 | March 20, 2026 |
| PINNACLE FINANCIAL PARTNERS INCPNFP · Entity 70624 | Director | March 01, 2024 | March 04, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CUMBERLAND PHARMACEUTICALS INC
Report date March 18, 2026 · Filed March 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 63,656 |
Reported balance
After 2026-03-18 transaction · row 1
1 source rowRow 1 · 2026-03-18 · Grant · Acquired 1,800 · Balance 63,656 |
PINNACLE FINANCIAL PARTNERS INC
Report date March 01, 2024 · Filed March 04, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| PNFP Common StockSEC Table I · non-derivative | Direct | 24,168 |
Ending reported balance
After 2024-03-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-03-01 · Tax withholding · Disposed 239 · Balance 23,179 F1: Represents shares withheld to cover taxes due upon the vesting of certain restricted share awards. Row 2 · 2024-03-01 · Grant · Acquired 989 · Balance 24,168 F2: Represents shares with restrictions that lapse on March 1, 2025 based on attendance at Pinnacle Board and Committee meetings to which the above-named director serves. |
| Depositary SharesSEC Table I · non-derivative | Direct | 4,000 |
Reported balance
Holding disclosure · report date 2024-03-01 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 4,000 F3: Each depositary share represents a 1/40th interest in a share of the Issuer's 6.75% Fixed-Rate Non-Cumulative Perpetual Preferred Stock, Series B, no par value per share. Depositary shares purchased in an underwritten public offering. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld to cover taxes due upon the vesting of certain restricted share awards.
F2: Represents shares with restrictions that lapse on March 1, 2025 based on attendance at Pinnacle Board and Committee meetings to which the above-named director serves.
F3: Each depositary share represents a 1/40th interest in a share of the Issuer's 6.75% Fixed-Rate Non-Cumulative Perpetual Preferred Stock, Series B, no par value per share. Depositary shares purchased in an underwritten public offering.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 17, 2019 Filed Jun 14, 2019 21:20 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 106 | $6.25 | $662.50 |
DisclosureSEC source: 0001209191-19-037200 · doc4.xml · nonDerivative · entry 13 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,548 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| May 14, 2019 Filed Jun 14, 2019 21:20 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 36 | $5.62 | $202.32 |
DisclosureSEC source: 0001209191-19-037200 · doc4.xml · nonDerivative · entry 12 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,442 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| May 10, 2019 Filed Jun 14, 2019 21:20 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 57 | $6.01 | $342.57 |
DisclosureSEC source: 0001209191-19-037200 · doc4.xml · nonDerivative · entry 11 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,406 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| May 08, 2019 Filed Jun 14, 2019 21:20 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 58 | $6.35 | $368.30 |
DisclosureSEC source: 0001209191-19-037200 · doc4.xml · nonDerivative · entry 10 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,349 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| May 07, 2019 Filed Jun 14, 2019 21:20 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 23 | $6.07 | $139.61 |
DisclosureSEC source: 0001209191-19-037200 · doc4.xml · nonDerivative · entry 9 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,291 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| May 06, 2019 Filed Jun 14, 2019 21:20 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 42 | $6.29 | $264.18 |
DisclosureSEC source: 0001209191-19-037200 · doc4.xml · nonDerivative · entry 8 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,268 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| May 02, 2019 Filed Jun 14, 2019 21:20 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 73 | $5.61 | $409.53 |
DisclosureSEC source: 0001209191-19-037200 · doc4.xml · nonDerivative · entry 7 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,226 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| April 30, 2019 Filed Jun 14, 2019 21:20 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 27 | $6.37 | $171.99 |
DisclosureSEC source: 0001209191-19-037200 · doc4.xml · nonDerivative · entry 6 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,153 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| April 26, 2019 Filed Jun 14, 2019 21:20 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 14 | $6.32 | $88.48 |
DisclosureSEC source: 0001209191-19-037200 · doc4.xml · nonDerivative · entry 5 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,126 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| April 25, 2019 Filed Jun 14, 2019 21:20 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 24 | $6.17 | $148.08 |
DisclosureSEC source: 0001209191-19-037200 · doc4.xml · nonDerivative · entry 4 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,112 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| April 24, 2019 Filed Jun 14, 2019 21:20 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 32 | $6.04 | $193.28 |
DisclosureSEC source: 0001209191-19-037200 · doc4.xml · nonDerivative · entry 3 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,088 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| April 17, 2019 Filed Jun 14, 2019 21:20 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 81 | $6.21 | $503.01 |
DisclosureSEC source: 0001209191-19-037200 · doc4.xml · nonDerivative · entry 2 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,056 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| April 12, 2019 Filed Jun 14, 2019 21:20 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 99 | $6.32 | $625.68 |
DisclosureSEC source: 0001209191-19-037200 · doc4.xml · nonDerivative · entry 1 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,975 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| April 09, 2019 Filed Apr 12, 2019 21:17 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 60 | $6.41 | $384.60 |
DisclosureSEC source: 0001209191-19-024503 · doc4.xml · nonDerivative · entry 6 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,876 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| April 05, 2019 Filed Apr 12, 2019 21:17 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 183 | $6.32 | $1,156.56 |
DisclosureSEC source: 0001209191-19-024503 · doc4.xml · nonDerivative · entry 5 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,816 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| April 03, 2019 Filed Apr 12, 2019 21:17 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 80 | $6.00 | $480.00 |
DisclosureSEC source: 0001209191-19-024503 · doc4.xml · nonDerivative · entry 3 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,392 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| April 02, 2019 Filed Apr 12, 2019 21:17 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 580 | $6.12 | $3,549.60 |
DisclosureSEC source: 0001209191-19-024503 · doc4.xml · nonDerivative · entry 2 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,312 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| April 01, 2019 Filed Apr 12, 2019 21:17 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 382 | $5.99 | $2,288.18 |
DisclosureSEC source: 0001209191-19-024503 · doc4.xml · nonDerivative · entry 1 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,732 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| March 22, 2019 Filed Mar 22, 2019 21:21 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 1,000 | $5.98 | $5,980.00 |
DisclosureSEC source: 0001209191-19-021045 · doc4.xml · nonDerivative · entry 1 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,350 F1 · shares: Restricted stock award will vest 100% on March 18, 2020. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 11:20 UTC | PINNACLE FINANCIAL PARTNERS INC PNFP · Entity 70624 | GrantPNFP Common Stock | 1,273 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-005904 · doc1.xml · nonDerivative · entry 2 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,679 F2 · shares: Represents shares with restrictions that lapse on February 29, 2020 based on attendance at Pinnacle Board and Committee meetings to which the above-named director serves. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 11:20 UTC | PINNACLE FINANCIAL PARTNERS INC PNFP · Entity 70624 | Tax withholdingPNFP Common Stock | 253 | $58.93 | $14,909.29 |
DisclosureSEC source: 0001567619-19-005904 · doc1.xml · nonDerivative · entry 1 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,406 F1 · shares: Represents shares withheld to cover taxes due upon the vesting of certain restricted share awards. Read SEC document |
| April 04, 2018 Filed Apr 12, 2019 21:17 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 241 | $6.19 | $1,491.79 |
DisclosureSEC source: 0001209191-19-024503 · doc4.xml · nonDerivative · entry 4 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,633 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| March 01, 2018 Filed Mar 2, 2018 15:46 UTC | PINNACLE FINANCIAL PARTNERS INC PNFP · Entity 70624 | GrantPNFP Common Stock | 1,148 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-011602 · doc1.xml · nonDerivative · entry 1 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,659 F1 · shares: Restricted shares with restrictions that lapse on February 28, 2019 based on attendance at Pinnacle Board and Committee meetings to which the above-named director serves. Read SEC document |
| September 07, 2017 Filed Sep 11, 2017 14:23 UTC | PINNACLE FINANCIAL PARTNERS INC PNFP · Entity 70624 | PurchasePNFP Common Stock | 500 | $58.95 | $29,475.00 |
DisclosureSEC source: 0001140361-17-035018 · doc1.xml · nonDerivative · entry 2 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,511 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $58.94 to $58.95. The reporting person undertakes to provide Pinnacle Financial Partners, Inc., any security holder of Pinnacle Financial Partners, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 07, 2017 Filed Sep 11, 2017 14:23 UTC | PINNACLE FINANCIAL PARTNERS INC PNFP · Entity 70624 | PurchasePNFP Common Stock | 500 | $59.85 | $29,925.00 |
DisclosureSEC source: 0001140361-17-035018 · doc1.xml · nonDerivative · entry 1 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,011 Read SEC document |
| May 31, 2017 Filed Jun 2, 2017 17:18 UTC | PINNACLE FINANCIAL PARTNERS INC PNFP · Entity 70624 | PurchasePNFP Common Stock | 1,000 | $59.73 | $59,725.00 |
DisclosureSEC source: 0001140361-17-023630 · doc1.xml · nonDerivative · entry 1 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,511 Read SEC document |
| May 17, 2017 Filed May 18, 2017 14:57 UTC | PINNACLE FINANCIAL PARTNERS INC PNFP · Entity 70624 | PurchasePNFP Common Stock | 100 | $59.75 | $5,975.00 |
DisclosureSEC source: 0001140361-17-021336 · doc1.xml · nonDerivative · entry 1 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,511 Read SEC document |
| March 01, 2017 Filed Mar 2, 2017 14:49 UTC | PINNACLE FINANCIAL PARTNERS INC PNFP · Entity 70624 | GrantPNFP Common Stock | 793 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-010251 · doc1.xml · nonDerivative · entry 1 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,411 F1 · shares: Restricted shares with restrictions that lapse on February 28, 2018 based on attendance at Pinnacle Board and Committee meetings to which the above-named director serves. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.